Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.21 (
CPT
)
4,580
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The predominant insulin-like growth factor binding protein (IGFBP) synthesized by PC12 rat phaeochromocytoma cells is
IGFBP-6
. Since cAMP agonists regulate
IGFBP-6
in other cells, and they may increase neurite outgrowth and catecholaminergic enzyme expression in PC12 cells, we studied regulation of
IGFBP-6
by these agents. After 72 h incubation, forskolin and 8-(4-chlorophenylthio)-cAMP (
CPT
-cAMP) both increased
IGFBP-6
protein levels in conditioned media to maximum levels of 231 +/- 40 and 275 +/- 30%, respectively. Incubation with forskolin resulted in a small, transient rise in
IGFBP-6
mRNA levels which was insufficient to account for the increased protein levels. The increased protein levels also could not be attributed to increased cell number, protection of
IGFBP-6
from proteolysis or release of
IGFBP-6
from a cell-associated reservoir. These findings suggest that increased protein levels may have been due to increased translation of mRNA. Co-incubation of forskolin with dexamethasone (which decreases
IGFBP-6
protein and mRNA) demonstrated that the effects of the latter were dominant. The effects of cAMP agonists and IGF-II, which increases
IGFBP-6
protein but not mRNA levels, were not inhibited by rapamycin, suggesting that p70 S6 kinase is not involved. The effects of cAMP agonists on
IGFBP-6
levels were not directly correlated with neurite outgrowth. These findings extend our knowledge of the molecular basis of the regulation of
IGFBP-6
by cAMP agonists, and indicate a novel action of these agents in PC12 cells.
...
PMID:Cyclic AMP agonists increase levels of insulin-like growth factor (IGF) binding protein-6 in PC12 rat phaeochromocytoma cells. 1098 15
